Joseph R. Berger, MD, looks forward to expanded discussions on the best treatment approaches for neuromyelitis optica spectrum disorders at the upcoming ECTRIMS 2024 meeting, including head-to-head ...
The agreement is a critical step in ensuring adult patients living with NMOSD and gMG have public access to Ultomiris MISSISSAUGA, ON, Aug. 7, 2025 /CNW/ - Alexion Pharma Canada Corp., AstraZeneca's ...
Joseph R. Berger, MD, shares significant insights regarding neuromyelitis optica spectrum disorders (NMOSD) presented at the recent ECTRIMS conference. Key findings focused on the disease's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback